Imine OTR Antagonists With Reduced V1aR Cross-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oxytocin receptor antagonists lack sufficient selectivity for oxytocin receptors (OTR) and vasopressin V1a receptors, leading to potential side effects and inefficiencies in treating conditions like premature delivery and sexual dysfunction.
Innovation Solution
Development of a novel imine compound with improved OTR antagonistic activity and reduced V1aR antagonistic activity, enhancing OTR/V1a target selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing oxytocin receptor antagonists are used, then oxytocin receptor blocking activity is achieved, but selectivity against vasopressin V1a receptors is insufficient leading to side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the imidazopyridine core structure. Different substituents (R1-R6) are placed at specific locations to create localized interactions that enhance OTR binding while reducing V1aR affinity, achieving selective blocking activity through spatially differentiated molecular properties
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, and functional groups on the imidazopyridine scaffold. These parameter modifications tune the molecular properties to optimize OTR selectivity over V1aR, transforming a non-selective antagonist into a selective one through controlled chemical parameter adjustment
2Adaptability or versatility
If broad-spectrum oxytocin receptor antagonists are used, then multiple conditions can be treated, but target selectivity between OTR and V1aR is compromised
Solution Approach 1:
The patent applies segmentation by dividing the pharmacological activity into distinct functional regions on the molecule. The imidazopyridine core provides baseline OTR antagonism, while specific substituent patterns (R1-R6) create a selective recognition element that segments the binding specificity, allowing the molecule to distinguish between OTR and V1aR receptors
Data Source
AI summary
The present disclosure relates to imine compounds as well as a preparation method therefor and the use thereof, in particular to compounds as shown in formula I. The compounds can be used for treating medical conditions such as premature delivery.